Cancer epigenetics
Open Access
- 15 April 2005
- journal article
- review article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 14 (suppl_1), R65-R76
- https://doi.org/10.1093/hmg/ddi113
Abstract
The field of cancer epigenetics is evolving rapidly on several fronts. Advances in our understanding of chromatin structure, histone modification, transcriptional activity and DNA methylation have resulted in an increasingly integrated view of epigenetics. In response to these insights, epigenetic therapy is expanding to include combinations of histone deacetylase inhibitors and DNA methyltransferase inhibitors. Zebularine, an orally administerable DNA methyltransferase inhibitor, has been a very promising recent addition to our arsenal of potentially useful drugs for epigenetic therapy. Aberrant DNA methylation patterns provide three powerful diagnostic applications as classification markers, sensitive detection markers, and risk assessment markers. Classification studies continue to increase in marker complexity, now incorporating microarrays, high-throughput bisulfite genomic sequencing and mass spectrometry, as the field moves to human epigenome projects. Sensitive detection technology has expanded from primarily blood-based cancer detection to include applications on a wide diversity of sample sources and is now also making inroads as a molecular risk assessment tool.Keywords
This publication has 181 references indexed in Scilit:
- CpG island methylator phenotype in cancerNature Reviews Cancer, 2004
- DNA Methylation Profiling of the Human Major Histocompatibility Complex: A Pilot Study for the Human Epigenome ProjectPLoS Biology, 2004
- Genetic analysis of genome-wide variation in human gene expressionNature, 2004
- Epigenetics in human disease and prospects for epigenetic therapyNature, 2004
- The power and the promise of DNA methylation markersNature Reviews Cancer, 2003
- Controlling the double helixNature, 2003
- DNA methylation in cancer: too much, but also too littleOncogene, 2002
- DNMT1 and DNMT3b cooperate to silence genes in human cancer cellsNature, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Aberrant CpG-island methylation has non-random and tumour-type–specific patternsNature Genetics, 2000